what is crypto coins- Top snippets

ZTE signed a strategic cooperation agreement with Daiyu and Midea Group. Recently, ZTE signed a strategic cooperation agreement with Daiyu and Midea Group in Chengdu. In the future, the two sides will carry out in-depth cooperation in VR space, AR application and MR interaction.US Treasury Department: US Treasury Secretary Yellen expressed appreciation for the close communication between the Ministry of Economic Affairs of Korea and the United States after the recent events in South Korea.Guohai Securities gave Youyou Food Co., Ltd. the initial rating of buying.

Oppenheimer: Raise the target price of opening customers from $980 to $1,075, and reiterate the rating of "outperforming the market".Syrian opposition forces claimed to have taken control of the eastern Syrian city of Deir ez-Zor. According to Al Jazeera and Arabiya TV, on the 10th local time, Hassan Abdel Ghani, commander of Syrian opposition forces, said that "the eastern Syrian city of Deir ez-Zor has been completely controlled".Trump appointed TOM BARRACK as the US ambassador to Turkey.

Tomato Fiction: In the coming year, 200 million yuan will be invested to support fine content. On December 11th, at the Tomato Fiction Creators' Conference, Tomato Fiction announced that it will invest 200 million yuan in cash to support fine content in 2025, and continue to launch a series of support plans to make efforts in IP ecology. In 2024, tomato novels launched more than 10 support programs, and a total of 120 million yuan of extra bonuses were distributed.Analyst: There may be a RRR cut of 50 basis points to 100 basis points next year. Tan Yiming, chief fixed income analyst of Minsheng Securities, said that there may be a RRR cut of 50 basis points to 100 basis points next year, considering the supply pressure of government bonds, the restoration of credit supply and the provision of long-term stable low-cost funds for financial institutions.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.